The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
The Predictive Value of Estimated Glomerular Filtration Rate (eGFR) for Adverse Cardiovascular Events in the Hospital in Patients With ST-segment Elevation
1 other identifier
observational
3
0 countries
N/A
Brief Summary
Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study is to research that the incidence of adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction is significantly higher when the glomerular filtration rate below a certain value.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2015
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2018
CompletedFirst Submitted
Initial submission to the registry
June 11, 2019
CompletedFirst Posted
Study publicly available on registry
June 12, 2019
CompletedJune 12, 2019
June 1, 2019
2.4 years
June 11, 2019
June 11, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
major adverse cardiac events
Relationship between reduced eGFR and in-hospital MACE
The median time of 7 days
Eligibility Criteria
STEMI Patients
You may qualify if:
- Patients with STEMI 2.Patients from whom informed consent has been properly obtained in writing prior to start of the trial
You may not qualify if:
- Patients with previous myocardial infarction, congenital heart disease 2.Patients with liver disease, and renal failure 3.Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dongying Zhanglead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 11, 2019
First Posted
June 12, 2019
Study Start
October 1, 2015
Primary Completion
February 28, 2018
Study Completion
February 28, 2018
Last Updated
June 12, 2019
Record last verified: 2019-06